Spots Global Cancer Trial Database for pnet
Every month we try and update this database with for pnet cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT01628913 | Pancreatic Neur... | BEZ235 Everolimus | 18 Years - | Novartis | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| Rare CNS Tumors Outcomes &Risk | NCT03251989 | High Grade Meni... Ependymoma Medulloblastoma PNET Primary CNS Sar... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors | NCT01381822 | Advanced Renal ... Gastrointestina... Pancreatic Neur... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors | NCT04074135 | VHL Pancreatic ... Von Hippel-Lind... Neuroendocrine ... | 68-Gallium DOTA... | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) | NCT03053999 | Multiple Endocr... Pancreatic Neur... Hyperparathyroi... | Genome Sequenci... Data Review | - | M.D. Anderson Cancer Center | |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | NCT00994071 | Medulloblastoma Pontine Glioma Ependymoma Astrocytoma PNET | Temozolomide ABT-888 | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | NCT02549937 | Tumors | surufatinib | 18 Years - | Hutchmed | |
| International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | NCT02066220 | Brain Tumors | Radiotherapy wi... Reduced-intensi... Radiotherapy wi... Maintenance che... WNT-HR < 16 yea... WNT-HR >= 16 ye... Induction Chemo... SHH-TP53 M0 SHH-TP53 M+ (ge... SHH-TP53 (somat... Vinblastin Main... | 3 Years - 21 Years | Universitätsklinikum Hamburg-Eppendorf | |
| BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | NCT01658436 | Pancreatic Neur... | BEZ235 (Stage 1... | 18 Years - | Novartis | |
| Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) | NCT03043508 | Genetic Mutatio... MEN1 | Chart Review Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT01628913 | Pancreatic Neur... | BEZ235 Everolimus | 18 Years - | Novartis | |
| Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors | NCT04074135 | VHL Pancreatic ... Von Hippel-Lind... Neuroendocrine ... | 68-Gallium DOTA... | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients | NCT03048266 | Multiple Endocr... | - | M.D. Anderson Cancer Center | ||
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors | NCT01381822 | Advanced Renal ... Gastrointestina... Pancreatic Neur... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy | NCT01222767 | Ewing's Sarcoma Primitive Neuro... Askin's Tumor o... Extraosseous Ew... | Zalypsis | 16 Years - | PharmaMar | |
| Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy | NCT01222767 | Ewing's Sarcoma Primitive Neuro... Askin's Tumor o... Extraosseous Ew... | Zalypsis | 16 Years - | PharmaMar | |
| Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | NCT01445288 | Diffuse Intrins... PNET Ependymoma Germinoma Medulloblastoma | 1 Month - 21 Years | National Institutes of Health Clinical Center (CC) | ||
| Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET | NCT01374451 | Islet Cell Tumo... | Everolimus Pasireotide LAR | 18 Years - | Novartis | |
| A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours | NCT02402062 | Neuroendocrine ... Pancreatic Neop... | TH-302 + Suniti... | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes | NCT01251913 | Ependymomas Gliomas PNET Pineal Tumors PCNSL (Primary ... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers | NCT02132468 | Neuroendocrine ... | fosbretabulin t... | 18 Years - | Mateon Therapeutics | |
| A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes | NCT01251913 | Ependymomas Gliomas PNET Pineal Tumors PCNSL (Primary ... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | NCT02355535 | Solid Tumor Pancreatic Neur... Neuroendocrine ... | PAC-1 | 18 Years - 85 Years | Vanquish Oncology, Inc. | |
| BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | NCT01658436 | Pancreatic Neur... | BEZ235 (Stage 1... | 18 Years - | Novartis | |
| HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | NCT02457845 | Supratentorial ... Malignant Gliom... Glioblastoma Anaplastic Astr... PNET Cerebral Primit... Embryonal Tumor | G207 | 3 Years - 18 Years | University of Alabama at Birmingham | |
| Rare CNS Tumors Outcomes &Risk | NCT03251989 | High Grade Meni... Ependymoma Medulloblastoma PNET Primary CNS Sar... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | NCT02355535 | Solid Tumor Pancreatic Neur... Neuroendocrine ... | PAC-1 | 18 Years - 85 Years | Vanquish Oncology, Inc. | |
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) | NCT03043508 | Genetic Mutatio... MEN1 | Chart Review Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | NCT00994071 | Medulloblastoma Pontine Glioma Ependymoma Astrocytoma PNET | Temozolomide ABT-888 | - 21 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
